Article ; Online: Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali.
The Journal of infectious diseases
2024 Volume 229, Issue 1, Page(s) 189–197
Abstract: Background: Owing to the increased cases of malaria in older children, the World Health Organization has recently recommended extending seasonal malaria chemoprevention (SMC) to children >5 years of age and using other effective drugs for malaria. In ... ...
Abstract | Background: Owing to the increased cases of malaria in older children, the World Health Organization has recently recommended extending seasonal malaria chemoprevention (SMC) to children >5 years of age and using other effective drugs for malaria. In this study, we report the safety and efficacy of dihydroartemisinin-piperaquine (DHA-PQ) for SMC in school-aged children in Mali. Method: This randomized, controlled trial included 345 participants aged 6-15 years randomized to receive DHA-PQ, sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ), or no chemoprevention (albendazole) at a 1:1:1 ratio. Four rounds of SMC were conducted from September to December 2021. The participants were assessed 7 days after each round for safety and efficacy of the interventions. Results: Abdominal pain (11.8% vs 29.2%), headache (11.2% vs 19.2%), and vomiting (5.7% vs 15.2%) were frequently reported in the DHA-PQ and SP-AQ arms. On Day 120 of follow up, the incidence of clinical malaria was 0.01 episodes/person-month in the DHA-PQ and SP-AQ arms and 0.17 episodes/person-month in the control arm (P < .0001). Gametocytes were detected in 37 participants in all arms. Conclusions: Children in DHA-PQ arm reported less adverse events compared to the SP-AQ arm. Both drugs were effective against clinical malaria and infection. |
---|---|
MeSH term(s) | Child ; Humans ; Infant ; Child, Preschool ; Antimalarials/adverse effects ; Mali/epidemiology ; Seasons ; Malaria/epidemiology ; Sulfadoxine/adverse effects ; Amodiaquine/adverse effects ; Drug Combinations ; Chemoprevention/adverse effects ; Piperazines ; Quinolines ; Artemisinins |
Chemical Substances | artenimol (6A9O50735X) ; Antimalarials ; piperaquine (A0HV2Q956Y) ; Sulfadoxine (88463U4SM5) ; Amodiaquine (220236ED28) ; Drug Combinations ; Piperazines ; Quinolines ; Artemisinins |
Language | English |
Publishing date | 2024-01-15 |
Publishing country | United States |
Document type | Randomized Controlled Trial ; Journal Article |
ZDB-ID | 3019-3 |
ISSN | 1537-6613 ; 0022-1899 |
ISSN (online) | 1537-6613 |
ISSN | 0022-1899 |
DOI | 10.1093/infdis/jiad387 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uh II Zs.50: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 445: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.